Owkin

Last updated
Owkin
Industry Biotechnology
FoundedAugust 3, 2016 (2016-08-03)
FounderThomas Clozel, Gilles Wainrib
Headquarters
Paris
,
France
Area served
US, France, UK, Switzerland, Germany, Spain
ProductsMSIntuit CRC, RlapsRisk BC
ServicesAI Drug Discovery, AI Drug Development, AI Diagnostics
Number of employees
350 (2023)
Website owkin.com

Owkin is an AI biotech company that uses artificial intelligence to identify new treatments, optimize clinical trials and develop AI diagnostics. [1] [2] The company uses federated learning, a type of privacy preserving technology, to access multimodal patient data from academic institutions and hospitals to train its AI models for drug discovery, development, and diagnostics. Owkin has collaborated with pharmaceutical companies around the world to improve their therapeutic programs. [3]

Contents

History

Owkin was founded in 2016, by Thomas Clozel, a clinical research doctor and son of Jean-Paul and Martine Clozel founders of Swiss biotech Actelion, and Gilles Wainrib, a professor of Artificial Intelligence. [4]

Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi. [5]

Technologies

Federated learning

Owkin uses federated learning, a decentralized machine learning technique, to train machine learning models with multiple data providers. [6] [7] [8] Federated learning allows data providers to collaborate without moving or sharing their data. [8] [7]

The MELLODDY project, an initiative that included Owkin, 10 pharmaceutical companies, and six other partners, applied federated learning to train AI on datasets without having to share proprietary data. [9] [8] [10] The aim was to improve drug discovery and they built a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). [9] [10] [8] The first results of the project were published in July 2022. [8]

Transfer learning

Transfer learning is a machine learning technique that allows a model pre-trained on one task to be used on another related task. [11] Owkin uses transfer learning to work on very small datasets. [11] Owkin's model (CHOWDER) is able to understand high-level graphic patterns, such as tumors, that are themselves relying on very low-level visual patterns, in order to fully learn the tumor's visual pattern. [12]

Products and Services

MSIntuit CRC

MSIntuit CRC is an AI-powered digital pre-screening diagnostic tool to improve colorectal cancer diagnosis and treatment. [13] It screens patients for microsatellite instability (MSI), which is a key genomic biomarker in colorectal cancer. [13] MSIntuit CRC is approved for use across the European Union. [14] It underwent a blind validation in 2023, made possibly partly by its availability within Medipath, the largest pathology lab network in France. [1]

Dx RlapsRisk BC

Dx RlapsRisk BC uses AI to predict if breast cancer patients will relapse within a few years of initial treatment. [14] It is used by pathologists and oncologists to help determine the right treatment pathway for breast cancer patients. [14]

Partnerships

Amgen

Owkin collaborated with Amgen to test the ability of AI to improve cardiovascular prediction. [3]

Sanofi

In November 2021 Owkin entered a strategic alliance with Sanofi. [15] The alliance included a $180 million equity investment, and a $90 million discovery and development partnership focused on Sanofi’s oncology efforts in four different cancers. [16] Sanofi used Owkin’s technology to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment. [17]

Bristol-Myers Squibb

In June 2022, Owkin entered a strategic alliance with Bristol-Myers Squibb to help them design potentially more precise and efficient clinical trials. [17] The collaboration initially focused on cardiovascular disease, and has the potential to expand into projects in other therapeutic areas. [18]

MSD

In December 2023, Owkin entered a strategic alliance with MSD to develop and commercialize AI-powered digital pathology diagnostics for the EU market that could be used to identify patients suitable for immunotherapies. [19]

Servier

In October 2023, Owkin and Servier started a multi-year partnership focused on developing “better-targeted therapies” in oncology and other disease areas. [20] The partnership’s first two projects were in translational medicine and digital pathology. [20]

MOSAIC

MOSAIC (Multi Omic Spatial Atlas in Cancer) was formed by Owkin, Nanostring Technologies, the University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité-Universitätsmedizin Berlin. [21] [22] It uses spatial omics, multimodal patient data, and artificial intelligence, and aims to “offer unprecedented information on the structure of tumors” and guide new treatments. [22] [21]

Publications

Owkin’s research on AI/ML has led to a number of publications that focus on machine learning methodologies and the development of predictive models for different disease areas, mainly oncology.

  1. Courtiol, Pierre et al. “Deep learning-based classification of mesothelioma improves prediction of patient outcome”, Nat Med 25, 1519–1525 (2019) [23]
  2. Schmauch, Benoît et al. “A deep learning model to predict RNA-Seq expression of tumours from whole slide images”, Nature Communications volume 11, Article number: 3877 (2020) [24]
  3. Jean Ogier du Terrail et al. “Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer" Nat Med (2023). 10.1038/s41591-022-02155 [25]
  4. Saiilard et al., “Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma” Nat Commun 14, 3459 (2023) [26]
  5. Saillard et al., “Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides” Nature Communications 14, 6695 (2023) [27]
  6. Saillard et al., "Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides" Hepatology 72 (2020) [28]

Awards

Related Research Articles

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Hereditary nonpolyposis colorectal cancer</span> Autosomal dominant genetic condition associated with a high risk of cancer in the colon

Hereditary nonpolyposis colorectal cancer (HNPCC) is a hereditary predisposition to colon cancer.

<span class="mw-page-title-main">Irofulven</span> Chemical compound

Irofulven or 6-hydroxymethylacylfulvene is an experimental antitumor agent. It belongs to the family of drugs called alkylating agents.

<span class="mw-page-title-main">Oxaliplatin</span> Pharmaceutical drug

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication used to treat colorectal cancer. It is given by injection into a vein.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

<span class="mw-page-title-main">Microsatellite instability</span> Condition of genetic hypermutability

Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). The presence of MSI represents phenotypic evidence that MMR is not functioning normally.

<span class="mw-page-title-main">KRAS</span> Protein-coding gene in humans

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

<span class="mw-page-title-main">Digital pathology</span>

Digital pathology is a sub-field of pathology that focuses on data management based on information generated from digitized specimen slides. Through the use of computer-based technology, digital pathology utilizes virtual microscopy. Glass slides are converted into digital slides that can be viewed, managed, shared and analyzed on a computer monitor. With the practice of whole-slide imaging (WSI), which is another name for virtual microscopy, the field of digital pathology is growing and has applications in diagnostic medicine, with the goal of achieving efficient and cheaper diagnoses, prognosis, and prediction of diseases due to the success in machine learning and artificial intelligence in healthcare.

Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in 1979 by Rolland-Yves Mauvernay.

<span class="mw-page-title-main">PARP inhibitor</span> Pharmacological enzyme inhibitors of poly (ADP-ribose) polymerases

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

<span class="mw-page-title-main">Lymphovascular invasion</span>

Lymphovascular invasion is the invasion of a cancer to the blood vessels and/or lymphatics.

<span class="mw-page-title-main">Google DeepMind</span> Artificial intelligence division

DeepMind Technologies Limited, doing business as Google DeepMind, is a British-American artificial intelligence research laboratory which serves as a subsidiary of Google. Founded in the UK in 2010, it was acquired by Google in 2014, the company is based in London, with research centres in Canada, France, Germany, and the United States.

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options. Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a 'personalized oncology' approach.

<span class="mw-page-title-main">Artificial intelligence in healthcare</span> Overview of the use of artificial intelligence in healthcare

Artificial intelligence in healthcare is a term used to describe the use of machine-learning algorithms and software, or artificial intelligence (AI), to copy human cognition in the analysis, presentation, and understanding of complex medical and health care data, or to exceed human capabilities by providing new ways to diagnose, treat, or prevent disease. Specifically, AI is the ability of computer algorithms to arrive at approximate conclusions based solely on input data.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

Sophia Genetics is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions. The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. The company went public on the Nasdaq in 2021, floating at $1.1B.

<span class="mw-page-title-main">Merative</span> U.S. healthcare company

Merative L.P., formerly IBM Watson Health, is an American medical technology company that provides products and services that help clients facilitate medical research, clinical research, real world evidence, and healthcare services, through the use of artificial intelligence, data analytics, cloud computing, and other advanced information technology. Merative is owned by Francisco Partners, an American private equity firm headquartered in San Francisco, California. In 2022, IBM divested and spun-off their Watson Health division into Merative. As of 2023, it remains a standalone company headquartered in Ann Arbor with innovation centers in Hyderabad, Bengaluru, and Chennai.

<span class="mw-page-title-main">Alberto Bardelli</span> Italian geneticist

Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.

References

  1. 1 2 "AI Steps Up to Streamline MSI Testing in Colorectal Cancer". AZoRobotics.com. 2023-11-07. Retrieved 2023-12-14.
  2. ↑ Alston, Fiona (2023-03-31). "French AI biotech unicorn Owkin has launched a €33 million AI-powered precision medicine project for cancer diagnosis and treatment". www.tech.eu. Retrieved 2023-11-01.
  3. 1 2 "Amgen, Owkin Use AI to Improve Cardiovascular Risk Prediction". Contract Pharma. Retrieved 2021-12-29.
  4. ↑ "Owkin heads to Basel". Basel Area Business & Innovation. Retrieved 2021-12-29.
  5. ↑ Rosemain, Mathieu (2021-11-18). "Drugmaker Sanofi invests $180 mln in French AI startup Owkin". Reuters. Retrieved 2021-12-29.
  6. ↑ Vinluan, Frank (2022-10-04). "Sanofi exec jumps to Owkin to ramp up the AI biotech's pharma partnership plans". MedCity News. Retrieved 2023-12-19.
  7. 1 2 Nanalyze (2020-01-27). "Federated Learning Explained Simply - Nanalyze". www.nanalyze.com. Retrieved 2023-12-19.
  8. 1 2 3 4 5 "L'apprentissage fédéré, le futur de la médecine basée sur les données - mind Health". www.mind.eu.com. Retrieved 2023-12-19.
  9. 1 2 Wiggers, Kyle (2020-09-17). "Major pharma companies, including Novartis and Merck, build federated learning platform for drug discovery". VentureBeat. Retrieved 2024-01-11.
  10. 1 2 "Federated Learning Can Protect Patients' Data In Hospitals". The Medical Futurist. 2021-04-13. Retrieved 2024-01-02.
  11. 1 2 outsourcing-pharma.com (2018-02-15). "OWKIN secures $11m to scale AI-driven drug discovery platform". outsourcing-pharma.com. Retrieved 2024-01-02.
  12. ↑ Saillard, Charlie; Dubois, Rémy; Tchita, Oussama; Loiseau, Nicolas; Garcia, Thierry; Adriansen, Aurélie; Carpentier, Séverine; Reyre, Joelle; Enea, Diana; von Loga, Katharina; Kamoun, Aurélie; Rossat, Stéphane; Wiscart, Corentin; Sefta, Meriem; Auffret, Michaël (2023-11-06). "Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides". Nature Communications. 14 (1): 6695. doi:10.1038/s41467-023-42453-6. ISSN   2041-1723. PMC   10628260 .
  13. 1 2 Thomas, Uduak (2023-11-10). "Owkin's AI Diagnostic for Colorectal Cancer Takes Center Stage with Promising Validation Results". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-12-20.
  14. 1 2 3 "Owkin AI for identifying breast, colorectal cancer types score EU approval". Fierce Biotech.
  15. ↑ "Sanofi inks $270M cancer AI deal with R&D platform developer Owkin". Fierce Biotech.
  16. ↑ "Drugmaker Sanofi invests $180 mln in French AI startup Owkin". Reuters.
  17. 1 2 Burroughs, Tasmin Lockwood, Callum. "Exclusive: Medical AI startup Owkin just secured $80 million as it gears up to enhance drug trials with the pharmaceutical giant Bristol Myers Squibb". Business Insider. Retrieved 2024-01-04.{{cite web}}: CS1 maint: multiple names: authors list (link)
  18. ↑ "BMS Enlists Owkin's AI/ML Tech to Improve Clinical Trials". BioSpace. Retrieved 2024-01-04.
  19. ↑ "Owkin and MSD join forces on AI-powered digital pathology". pharmaphorum. Retrieved 2024-03-01.
  20. 1 2 "Owkin signs up another pharma partner for its AI platform". pharmaphorum. Retrieved 2024-03-14.
  21. 1 2 "ASCO: AI-powered MOSAIC will build 3D atlas for cancer". pharmaphorum. Retrieved 2024-03-06.
  22. 1 2 outsourcing-pharma.com (2023-06-08). "Owkin invests $50M in spatial omics project that will 'revolutionize cancer research'". outsourcing-pharma.com. Retrieved 2024-03-06.
  23. ↑ Courtiol, Pierre; Maussion, Charles; Moarii, Matahi; Pronier, Elodie; Pilcer, Samuel; Sefta, Meriem; Manceron, Pierre; Toldo, Sylvain; Zaslavskiy, Mikhail; Le Stang, Nolwenn; Girard, Nicolas; Elemento, Olivier; Nicholson, Andrew G.; Blay, Jean-Yves; Galateau-Sallé, Françoise (October 2019). "Deep learning-based classification of mesothelioma improves prediction of patient outcome". Nature Medicine. 25 (10): 1519–1525. doi:10.1038/s41591-019-0583-3. ISSN   1078-8956.
  24. ↑ Schmauch, Benoît; Romagnoni, Alberto; Pronier, Elodie; Saillard, Charlie; Maillé, Pascale; Calderaro, Julien; Kamoun, Aurélie; Sefta, Meriem; Toldo, Sylvain; Zaslavskiy, Mikhail; Clozel, Thomas; Moarii, Matahi; Courtiol, Pierre; Wainrib, Gilles (2020-08-03). "A deep learning model to predict RNA-Seq expression of tumours from whole slide images". Nature Communications. 11 (1): 3877. doi: 10.1038/s41467-020-17678-4 . ISSN   2041-1723.
  25. ↑ Ogier du Terrail, Jean; Leopold, Armand; Joly, Clément; Béguier, Constance; Andreux, Mathieu; Maussion, Charles; Schmauch, Benoît; Tramel, Eric W.; Bendjebbar, Etienne; Zaslavskiy, Mikhail; Wainrib, Gilles; Milder, Maud; Gervasoni, Julie; Guerin, Julien; Durand, Thierry (January 2023). "Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer". Nature Medicine. 29 (1): 135–146. doi:10.1038/s41591-022-02155-w. ISSN   1546-170X.
  26. ↑ Saillard, Charlie; Delecourt, Flore; Schmauch, Benoit; Moindrot, Olivier; Svrcek, Magali; Bardier-Dupas, Armelle; Emile, Jean Francois; Ayadi, Mira; Rebours, Vinciane; de Mestier, Louis; Hammel, Pascal; Neuzillet, Cindy; Bachet, Jean Baptiste; Iovanna, Juan; Dusetti, Nelson (2023-06-13). "Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma". Nature Communications. 14 (1): 3459. doi:10.1038/s41467-023-39026-y. ISSN   2041-1723.
  27. ↑ Saillard, Charlie; Dubois, Rémy; Tchita, Oussama; Loiseau, Nicolas; Garcia, Thierry; Adriansen, Aurélie; Carpentier, Séverine; Reyre, Joelle; Enea, Diana; von Loga, Katharina; Kamoun, Aurélie; Rossat, Stéphane; Wiscart, Corentin; Sefta, Meriem; Auffret, Michaël (2023-11-06). "Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides". Nature Communications. 14 (1): 6695. doi:10.1038/s41467-023-42453-6. ISSN   2041-1723. PMC   10628260 .
  28. ↑ Saillard, Charlie; Schmauch, Benoit; Laifa, Oumeima; Moarii, Matahi; Toldo, Sylvain; Zaslavskiy, Mikhail; Pronier, Elodie; Laurent, Alexis; Amaddeo, Giuliana; Regnault, Hélène; Sommacale, Daniele; Ziol, Marianne; Pawlotsky, Jean-Michel; Mulé, Sébastien; Luciani, Alain (December 2020). "Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides". Hepatology. 72 (6): 2000. doi:10.1002/hep.31207. ISSN   0270-9139.
  29. ↑ Maignan, Iris (2019-09-13). "3 informations pour bien commencer la journée : Chaire Good In Tech, les Rebondisseurs, et Owkin". Maddyness - Le média pour comprendre l'économie de demain (in French). Retrieved 2024-01-30.
  30. ↑ Hamilton-Basich, Melanie (2020-10-05). "Prix Galien Nominees for Best Digital Health Product Announced". 24x7. Retrieved 2024-01-30.
  31. ↑ "Tech For Good Awards: découvrez les gagnants de l'édition 2021". BFM BUSINESS (in French). Retrieved 2024-01-26.
  32. ↑ "2021 Member Recognition Awards Recognize Impactful Initiatives in the FACC-NY Network". www.faccnyc.org. Retrieved 2024-01-26.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.